Differences between interferon-α and-β treatment for patients with chronic hepatitis C virus infection

Norihiro Furusyo, Jun Hayashi, Misako Ohmiya, Yasunori Sawayama, Yasunobu Kawakami, Iwao Ariyama, Naoko Kinukawa, Seizaburo Kashiwagi

Research output: Contribution to journalArticle

37 Citations (Scopus)

Abstract

To compare virological, biochemical, and immune responses to human lymphoblastoid interferon (IFN-α) and human fibroblast interferon (IFN-β) in patients with chronic hepatitis C virus (HCV) infection, 120 patients were randomly assigned to three groups (group A, 60 patients receiving IFN-α, 6 million units (MU) once a day, daily for one month and thrice weekly for five months; group B, 40 patients receiving 6 MU IFN-β once a day daily for two months; and group C, 20 patients receiving 3 MU IFN-β twice a day (6 MU/day) daily for two months). Serum soluble interleukin-2 receptor (sIL-2R) and interleukin-6 (IL-6) levels were measured by enzyme-linked immunosorbent assay. Patients with sustained clearance of serum HCV RNA detected by polymerase chain reaction (PCR) at six months after IFN treatment were defined as having complete response to IFN treatment. A low level of HCV RNA (≤104 copies/50 μl, measured by competitive PCR) and HCV RNA of genotype 2a were favorable factors for a complete response to both IFNs. Complete response in group A treatment was strongly associated with early HCV RNA clearance, in contrast with group B. A significantly higher HCV RNA negativity at the second week from start of treatment was noted in group C (80.0%), compared with groups A (41.6%) and B (27.5%). sIL-2R levels rose in each group during IFN administration. In group C, alanine aminotransferase (ALT) and IL-6 levels were remarkably elevated. These findings indicate that timing of serum HCV RNA negativity in sustained response differs between IFN- α and IFN-β administrations and that early HCV RNA clearance was induced by twice-a-day IFN-β treatment.

Original languageEnglish
Pages (from-to)608-617
Number of pages10
JournalDigestive Diseases and Sciences
Volume44
Issue number3
DOIs
Publication statusPublished - Jan 1 1999

All Science Journal Classification (ASJC) codes

  • Physiology
  • Gastroenterology

Fingerprint Dive into the research topics of 'Differences between interferon-α and-β treatment for patients with chronic hepatitis C virus infection'. Together they form a unique fingerprint.

  • Cite this

    Furusyo, N., Hayashi, J., Ohmiya, M., Sawayama, Y., Kawakami, Y., Ariyama, I., Kinukawa, N., & Kashiwagi, S. (1999). Differences between interferon-α and-β treatment for patients with chronic hepatitis C virus infection. Digestive Diseases and Sciences, 44(3), 608-617. https://doi.org/10.1023/A:1026625928117